0.1799
14.66%
+0.023
Pre-market:
.1528
-0.0271
-15.06%
Jaguar Health Inc stock is currently priced at $0.1799, with a 24-hour trading volume of 100.90M.
It has seen a +14.66% increased in the last 24 hours and a +150.21% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.1611 pivot point. If it approaches the $0.1805 resistance level, significant changes may occur.
Jaguar Health Inc Stock (JAGX) Financials Data
Jaguar Health Inc (JAGX) Revenue 2024
JAGX reported a revenue (TTM) of $10.72 million for the quarter ending September 30, 2023, a -0.51% decline year-over-year.
Jaguar Health Inc (JAGX) Net Income 2024
JAGX net income (TTM) was -$39.71 million for the quarter ending September 30, 2023, a +26.71% increase year-over-year.
Jaguar Health Inc (JAGX) Cash Flow 2024
JAGX recorded a free cash flow (TTM) of -$32.21 million for the quarter ending September 30, 2023, a +12.74% increase year-over-year.
Jaguar Health Inc (JAGX) Earnings per Share 2024
JAGX earnings per share (TTM) was -$6.9342 for the quarter ending September 30, 2023, a +88.98% growth year-over-year.
Jaguar Health Inc Stock (JAGX) Latest News
Using Economic News to Profit With Penny Stocks
PennyStocks
S&P 500 Edges Lower; PacBio Shares Plunge
Benzinga
Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga
Gold Moves Higher; Morgan Stanley Earnings Top Views
Benzinga
Don’t Trade Penny Stocks Until You’ve Taken These Steps
PennyStocks
Can You Predict Penny Stock Breakouts? 3 Tips
PennyStocks
About Jaguar Health Inc
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.
Cap:
|
Volume (24h):